Emily K. Law

Emily K. Law

Auto-generated profile, based on publicly available information

Emily K. Law

Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ELEmily K. Law
Emily K. Law
RLRena Levin-Klein
Rena Levin-Klein
MJMatthew C. Jarvis
Matthew C. Jarvis
HKHyoung Kim
Hyoung Kim
PAProkopios P. Argyris
Prokopios P. Argyris
RHReuben Harris
Reuben Harris
The APOBEC3 family of antiviral DNA cytosine deaminases is implicated as the second largest source of mutation in cancer. This mutational process may be a causal driver or inconsequential passenger to the overall tumor phenotype. We show that human APOBEC3A expression in murine colon and liver tissues increases tumorigenesis. All other APOBEC3 family members, including APOBEC3B, fail to promote liver tumor formation. Tumor DNA sequences from APOBEC3A-expressing animals display hallmark APOBEC signature mutations in TCA/T motifs. Bioinformatic comparisons of the observed APOBEC3A mutation signature in murine tumors, previously reported APOBEC3A and APOBEC3B mutation signatures in yeast, and reanalyzed APOBEC mutation signatures in human tumor datasets support cause-and-effect relationships for APOBEC3A-catalyzed deamination and mutagenesis in driving multiple human cancers.

4 December 2023 in Nature Genetics
Verified
Journal Article
Open access
PDF file
DCDeborah R. Caswell
Deborah R. Caswell
PGPhilippe Gui
Philippe Gui
MMManasi K. Mayekar
Manasi K. Mayekar
ELEmily K. Law
Emily K. Law
OPOriol Pich
Oriol Pich
CSCharles Swanton
Charles Swanton
In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like (APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven lung cancer was assessed. A3B expression in EGFR mutant (EGFRmut) non-small-cell lung cancer (NSCLC) mouse models constrained tumorigenesis, while A3B expression in tumors treated with EGFR-targeted cancer therapy was associated with treatment resistance. Analyses of human NSCLC models treated with EGFR-targeted therapy showed upregulation of A3B and revealed therapy-induced activation of nuclear factor kappa B (NF-κB) as an inducer of A3B expression. Significantly reduced viability was observed with A3B deficiency, and A3B was required for the enrichment of APOBEC mutation signatures, in targeted therapy-treated human NSCLC preclinical models. Upregulation of A3B was confirmed in patients with NSCLC treated with EGFR-targeted therapy. This study uncovers the multifaceted roles of A3B in NSCLC and identifies A3B as a potential target for more durable responses to targeted cancer therapy.

5 August 2022 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JBJesse Boumelha
Jesse Boumelha
STSophie de Carné Trécesson
Sophie de Carné Trécesson
ELEmily K. Law
Emily K. Law
PRPablo Romero-Clavijo
Pablo Romero-Clavijo
MCMatthew A. Coelho
Matthew A. Coelho
JDJulian Downward
Julian Downward
Mutations in oncogenes such as KRAS and EGFR cause a high proportion of lung cancers. Drugs targeting these proteins cause tumor regression but ultimately fail to elicit cures. As a result, there is an intense interest in how to best combine targeted therapies with other treatments, such as immunotherapies. However, preclinical systems for studying the interaction of lung tumors with the host immune system are inadequate, in part due to the low tumor mutational burden in genetically engineered mouse models. Here we set out to develop mouse models of mutant KRAS–driven lung cancer with an elevated tumor mutational burden by expressing the human DNA cytosine deaminase, APOBEC3B, to mimic the mutational signature seen in human lung cancer. This failed to substantially increase clonal tumor mutational burden and autochthonous tumors remained refractory to immunotherapy. However, establishing clonal cell lines from these tumors enabled the generation of an immunogenic syngeneic transplantation model of KRAS-mutant lung adenocarcinoma that was sensitive to immunotherapy. Unexpectedly, antitumor immune responses were not directed against neoantigens but instead targeted derepressed endogenous retroviral antigens. The ability of KRASG12C inhibitors to cause regression of KRASG12C -expressing tumors was markedly potentiated by the adaptive immune system, highlighting the importance of using immunocompetent models for evaluating targeted therapies. Overall, this model provides a unique opportunity for the study of combinations of targeted and immunotherapies in immune-hot lung cancer. Significance: This study develops a mouse model of immunogenic KRAS-mutant lung cancer to facilitate the investigation of optimal combinations of targeted therapies with immunotherapies.

21 September 2023 in Nature Genetics
Verified
Journal Article
Open access
PDF file
JMJennifer L. McCann
Jennifer L. McCann
ACAgnese Cristini
Agnese Cristini
ELEmily K. Law
Emily K. Law
SLSeo Yun Lee
Seo Yun Lee
MTMichael Tellier
Michael Tellier
RHReuben Harris
Reuben Harris
The single-stranded DNA cytosine-to-uracil deaminase APOBEC3B is an antiviral protein implicated in cancer. However, its substrates in cells are not fully delineated. Here APOBEC3B proteomics reveal interactions with a surprising number of R-loop factors. Biochemical experiments show APOBEC3B binding to R-loops in cells and in vitro. Genetic experiments demonstrate R-loop increases in cells lacking APOBEC3B and decreases in cells overexpressing APOBEC3B. Genome-wide analyses show major changes in the overall landscape of physiological and stimulus-induced R-loops with thousands of differentially altered regions, as well as binding of APOBEC3B to many of these sites. APOBEC3 mutagenesis impacts genes overexpressed in tumors and splice factor mutant tumors preferentially, and APOBEC3-attributed kataegis are enriched in RTCW motifs consistent with APOBEC3B deamination. Taken together with the fact that APOBEC3B binds single-stranded DNA and RNA and preferentially deaminates DNA, these results support a mechanism in which APOBEC3B regulates R-loops and contributes to R-loop mutagenesis in cancer.

31 March 2023
Verified
Other
Open access
JBJesse Boumelha
Jesse Boumelha
STSophie de Carné Trécesson
Sophie de Carné Trécesson
ELEmily K. Law
Emily K. Law
PRPablo Romero-Clavijo
Pablo Romero-Clavijo
MCMatthew A. Coelho
Matthew A. Coelho
JDJulian Downward
Julian Downward
Supplementary Table from An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations

31 March 2023
Verified
Other
Open access
JBJesse Boumelha
Jesse Boumelha
STSophie de Carné Trécesson
Sophie de Carné Trécesson
ELEmily K. Law
Emily K. Law
PRPablo Romero-Clavijo
Pablo Romero-Clavijo
MCMatthew A. Coelho
Matthew A. Coelho
JDJulian Downward
Julian Downward
Supplementary Table from An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations